Atrial fibrillation-associated electrical remodelling in human induced pluripotent stem cell-derived atrial cardiomyocytes: a novel pathway for antiarrhythmic therapy development.
Action potential
Atrial fibrillation
Ion channel
Optogenetics
Stem cells
Journal
Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427
Informations de publication
Date de publication:
19 12 2023
19 12 2023
Historique:
received:
28
09
2022
revised:
18
07
2023
accepted:
03
08
2023
medline:
21
12
2023
pubmed:
7
9
2023
entrez:
7
9
2023
Statut:
ppublish
Résumé
Atrial fibrillation (AF) is associated with tachycardia-induced cellular electrophysiology alterations which promote AF chronification and treatment resistance. Development of novel antiarrhythmic therapies is hampered by the absence of scalable experimental human models that reflect AF-associated electrical remodelling. Therefore, we aimed to assess if AF-associated remodelling of cellular electrophysiology can be simulated in human atrial-like cardiomyocytes derived from induced pluripotent stem cells in the presence of retinoic acid (iPSC-aCM), and atrial-engineered human myocardium (aEHM) under short term (24 h) and chronic (7 days) tachypacing (TP). First, 24-h electrical pacing at 3 Hz was used to investigate whether AF-associated remodelling in iPSC-aCM and aEHM would ensue. Compared to controls (24 h, 1 Hz pacing) TP-stimulated iPSC-aCM presented classical hallmarks of AF-associated remodelling: (i) decreased L-type Ca2+ current (ICa,L) and (ii) impaired activation of acetylcholine-activated inward-rectifier K+ current (IK,ACh). This resulted in action potential shortening and an absent response to the M-receptor agonist carbachol in both iPSC-aCM and aEHM subjected to TP. Accordingly, mRNA expression of the channel-subunit Kir3.4 was reduced. Selective IK,ACh blockade with tertiapin reduced basal inward-rectifier K+ current only in iPSC-aCM subjected to TP, thereby unmasking an agonist-independent constitutively active IK,ACh. To allow for long-term TP, we developed iPSC-aCM and aEHM expressing the light-gated ion-channel f-Chrimson. The same hallmarks of AF-associated remodelling were observed after optical-TP. In addition, continuous TP (7 days) led to (i) increased amplitude of inward-rectifier K+ current (IK1), (ii) hyperpolarization of the resting membrane potential, (iii) increased action potential-amplitude and upstroke velocity as well as (iv) reversibly impaired contractile function in aEHM. Classical hallmarks of AF-associated remodelling were mimicked through TP of iPSC-aCM and aEHM. The use of the ultrafast f-Chrimson depolarizing ion channel allowed us to model the time-dependence of AF-associated remodelling in vitro for the first time. The observation of electrical remodelling with associated reversible contractile dysfunction offers a novel platform for human-centric discovery of antiarrhythmic therapies.
Identifiants
pubmed: 37677054
pii: 7263227
doi: 10.1093/cvr/cvad143
pmc: PMC10730244
doi:
Substances chimiques
Anti-Arrhythmia Agents
0
Acetylcholine
N9YNS0M02X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2623-2637Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : DFG, VO 1568/3-1, VO 1568/4-1, IRTG1816 project 12, SFB1002
Organisme : German Center for Cardiovascular Research
ID : 81X2300189 and 81X4300102
Organisme : BMBF
ID : 01GM1902D
Organisme : Göttingen Promotionskolleg für Medizinstudierende
Organisme : Jacob-Henle-Programm
Organisme : Else-Kröner-Fresenius-Stiftung
Organisme : DZHK
Organisme : Fondation Leducq
ID : 20CVD04
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
Déclaration de conflit d'intérêts
Conflict of interest: W.H.Z. is founder and advisor of Repairon GmbH and myriamed GmbH. M.T. is advisor of Repairon GmbH and myriamed GmbH. myriamed GmbH commercializes iPSC-based cell and tissue models for drug discovery. M.Rap. is an employee of Nanion Technologies GmbH. This manuscript was handled by Consulting Editor David Eisner.
Références
Circulation. 2015 Jul 14;132(2):82-92
pubmed: 25951834
Eur Heart J. 2023 Jul 14;44(27):2483-2494
pubmed: 36810794
Circulation. 2005 Dec 13;112(24):3697-706
pubmed: 16330682
Circulation. 2004 Oct 19;110(16):2299-306
pubmed: 15477405
Circulation. 2014 Jan 14;129(2):145-156
pubmed: 24249718
Nat Commun. 2018 May 1;9(1):1750
pubmed: 29717130
Eur Heart J. 2017 Jun 07;38(22):1764-1774
pubmed: 28057773
Am J Physiol Heart Circ Physiol. 2013 Jul 1;305(1):H66-75
pubmed: 23645460
Card Electrophysiol Clin. 2016 Jun;8(2):411-21
pubmed: 27261831
Nat Commun. 2020 Jan 7;11(1):75
pubmed: 31911598
J Physiol. 2007 Jul 15;582(Pt 2):675-93
pubmed: 17478540
J Mol Cell Cardiol. 2013 Aug;61:142-52
pubmed: 23531443
Circ Res. 2014 Apr 25;114(9):1483-99
pubmed: 24763466
Circ Res. 2008 Oct 10;103(8):845-54
pubmed: 18723446
J Cardiovasc Pharmacol. 2013 May;61(5):408-15
pubmed: 23364608
Circ Res. 1997 Oct;81(4):512-25
pubmed: 9314832
Cell Res. 2011 Apr;21(4):579-87
pubmed: 21102549
Int J Cardiol. 2018 Mar 15;255:61-68
pubmed: 29290419
Circ Res. 2011 Oct 28;109(10):1105-14
pubmed: 21921264
Circ Arrhythm Electrophysiol. 2010 Oct;3(5):472-80
pubmed: 20657029
Circ Res. 2020 Jun 19;127(1):51-72
pubmed: 32717172
Clin Res Cardiol. 2019 Jun;108(6):577-599
pubmed: 30306295
Circ Res. 2009 Oct 23;105(9):876-85
pubmed: 19762679
Basic Res Cardiol. 2020 Nov 30;115(6):72
pubmed: 33258071
Cardiovasc Res. 2007 Jun 1;74(3):426-37
pubmed: 17362895
JCI Insight. 2018 Jun 21;3(12):
pubmed: 29925689
Stem Cell Res. 2020 Oct;48:101944
pubmed: 33038615
Europace. 2013 May;15(5):754-60
pubmed: 23419660
Circulation. 2012 May 1;125(17):2059-70
pubmed: 22456474
J Vis Exp. 2020 Dec 22;(166):
pubmed: 33427238
Heart Rhythm. 2005 Mar;2(3):223-30
pubmed: 15851308
Circulation. 1998 Dec 1;98(22):2422-8
pubmed: 9832487
Eur Heart J. 2013 Apr;34(15):1134-46
pubmed: 23103664
Circ Res. 2007 Feb 16;100(3):425-33
pubmed: 17234964
Acta Physiol Scand. 1993 Oct;149(2):133-42
pubmed: 8266802
J Physiol. 2004 Jun 1;557(Pt 2):583-97
pubmed: 15020696
Cell. 2019 Feb 7;176(4):913-927.e18
pubmed: 30686581
J Clin Invest. 2014 Nov;124(11):4759-72
pubmed: 25329692
J Pharmacol Exp Ther. 2013 Oct;347(1):69-79
pubmed: 23887096
Curr Opin Pharmacol. 2014 Apr;15:16-21
pubmed: 24721649
EMBO Mol Med. 2015 Feb 19;7(4):394-410
pubmed: 25700171
Stem Cell Rev Rep. 2011 Nov;7(4):976-86
pubmed: 21614516
Cardiovasc Res. 2008 Jan;77(1):35-43
pubmed: 18006448
Front Cell Dev Biol. 2020 Jul 28;8:536
pubmed: 32850774
Cardiovasc Res. 2020 Jul 1;116(8):1487-1499
pubmed: 31598634
Front Physiol. 2018 Oct 08;9:1227
pubmed: 30349482
Circulation. 2017 May 9;135(19):1832-1847
pubmed: 28167635
Br J Pharmacol. 2008 Aug;154(8):1619-30
pubmed: 18536759
Cardiovasc Res. 2021 Jun 16;117(7):1718-1731
pubmed: 33982075
Europace. 2010 Feb;12(2):160-72
pubmed: 19875395
Sci Rep. 2017 Jul 13;7(1):5268
pubmed: 28706272
Circ Res. 1999 Sep 3;85(5):428-36
pubmed: 10473672
Cardiovasc Drugs Ther. 2017 Jun;31(3):325-344
pubmed: 28721524
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
Life Sci. 2014 Mar 3;97(2):107-15
pubmed: 24345461
Circ Res. 2011 Oct 14;109(9):1031-43
pubmed: 21903936
Stem Cell Reports. 2015 Oct 13;5(4):647-59
pubmed: 26411904
Cardiovasc Res. 2021 Jun 16;117(7):1790-1801
pubmed: 32520995
Biomaterials. 2013 Mar;34(10):2399-411
pubmed: 23261219
J Physiol. 2016 Feb 1;594(3):537-53
pubmed: 26582329
Stem Cell Reports. 2018 Dec 11;11(6):1378-1390
pubmed: 30416051
J Clin Invest. 2013 May;123(5):1939-51
pubmed: 23543060
Cardiovasc Res. 2022 Jun 22;118(7):1613-1614
pubmed: 35425974
Cardiovasc Res. 2020 May 1;116(6):1147-1160
pubmed: 31504264
Dis Model Mech. 2019 Jul 9;12(7):
pubmed: 31208990
STAR Protoc. 2020 Jun 03;1(1):100032
pubmed: 33111083
Circ Res. 2020 Jun 19;127(1):21-33
pubmed: 32716721
J Am Coll Cardiol. 2003 Mar 5;41(5):858-69
pubmed: 12628735
Commun Biol. 2022 Sep 15;5(1):969
pubmed: 36109584
Cardiovasc Res. 2005 Jul 1;67(1):69-76
pubmed: 15949471
Cell Stem Cell. 2017 Aug 3;21(2):179-194.e4
pubmed: 28777944
Development. 2017 Mar 15;144(6):1008-1017
pubmed: 28279973
Circulation. 2004 Oct 26;110(17):2651-7
pubmed: 15492323
Circ Res. 2020 Jun 19;127(1):91-110
pubmed: 32716814
Cardiovasc Res. 1999 May;42(2):434-42
pubmed: 10533579
Elife. 2017 Jan 30;6:
pubmed: 28134617
STAR Protoc. 2020 Jun 03;1(1):100026
pubmed: 33111079
Circulation. 2020 Sep 29;142(13):1261-1278
pubmed: 32686471
Basic Res Cardiol. 2022 May 2;117(1):5
pubmed: 35499658
Water Res. 2018 Jan 1;128:314-330
pubmed: 29107916
J Cardiovasc Pharmacol. 2020 Dec 13;77(3):291-299
pubmed: 33278190
Sci Rep. 2015 Oct 21;5:15187
pubmed: 26487066
Circulation. 1995 Oct 1;92(7):1954-68
pubmed: 7671380